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Noonan syndrome (NS) is a developmental disorder characterized by facial dysmorphia, short stature, cardiac
defects, and skeletal malformations. We recently demonstrated that mutations in PTPN11, the gene encoding the
non–receptor-type protein tyrosine phosphatase SHP-2 (src homology region 2-domain phosphatase–2), cause NS,
accounting for ∼50% of cases of this genetically heterogeneous disorder in a small cohort. All mutations were
missense changes and clustered at the interacting portions of the amino-terminal src-homology 2 (N-SH2) and
protein tyrosine phosphatase (PTP) domains. A gain of function was postulated as a mechanism for the disease.
Here, we report the spectrum and distribution of PTPN11 mutations in a large, well-characterized cohort with NS.
Mutations were found in 54 of 119 (45%) unrelated individuals with sporadic or familial NS. There was a
significantly higher prevalence of mutations among familial cases than among sporadic ones. All defects were
missense, and several were recurrent. The vast majority of mutations altered amino acid residues located in or
around the interacting surfaces of the N-SH2 and PTP domains, but defects also affected residues in the C-SH2
domain, as well as in the peptide linking the N-SH2 and C-SH2 domains. Genotype-phenotype analysis revealed
that pulmonic stenosis was more prevalent among the group of subjects with NS who had PTPN11 mutations than
it was in the group without them (70.6% vs. 46.2%; ), whereas hypertrophic cardiomyopathy was lessP ! .01
prevalent among those with PTPN11 mutations (5.9% vs. 26.2%; ). The prevalence of other congenitalP ! .005
heart malformations, short stature, pectus deformity, cryptorchidism, and developmental delay did not differ between
the two groups. A PTPN11 mutation was identified in a family inheriting Noonan-like/multiple giant-cell lesion
syndrome, extending the phenotypic range of disease associated with this gene.
Introduction
Noonan syndrome (NS [MIM 163950]), which was first
recognized as distinct entity almost 40 years ago, is a
clinically heterogeneous disorder defined by short stat-
ure, facial dysmorphia, and a wide spectrum of congen-
ital heart defects (Noonan 1968; Allanson 1987). The
distinctive facial features consist of a broad forehead,
hypertelorism, down-slanting palpebral fissures, a high-
arched palate, and low-set, posteriorly rotated ears. Car-
diac involvement is present in up to 90% of affected
individuals. Pulmonic stenosis and hypertrophic car-
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diomyopathy (HCM) are the most common forms of
cardiac disease in NS, but a wide range of other lesions,
including atrioventricular septal defects and aortic co-
arctation, are also observed (Marino et al. 1999; Bertola
et al. 2000). Additional relatively frequent features of
NS include multiple skeletal defects (chest and spine de-
formities), webbed neck, mental retardation, cryptor-
chidism, and bleeding diasthesis. Although precise epi-
demiological data are not available, the prevalence of
NS is estimated to be between 1:1,000 and 1:2,500 live
births (Nora et al. 1974).
From a genetic point of view, NS was a poorly un-
derstood condition until recently. Autosomal dominant
inheritance is apparent for the majority of families with
the disorder, although there is evidence for an autosomal
recessive form of NS (van der Burgt and Brunner 2000).
A locus at chromosomal band 12q24 (NS1) was estab-
lished in a study of two large families inheriting NS
(Jamieson et al. 1994; Brady et al. 1997; Legius et al.
1998). Genetic heterogeneity was also documented on
the basis of linkage exclusion (Jamieson et al. 1994).
1556 Am. J. Hum. Genet. 70:1555–1563, 2002
Recently, PTPN11, which encodes the non–receptor-
type protein tyrosine phosphatase SHP-2 (src homology
region 2-domain phosphatase–2), was identified as the
NS1 disease gene, through use of a positional candidacy
approach (Tartaglia et al. 2001). Missense mutations in
PTPN11 accounted for 50% of cases in a cohort of 22
unrelated subjects with familial or sporadic NS (Tar-
taglia et al. 2001).
SHP-2 (previouslynamed“Syp,”“SH-PTP2,”“PTP1D,”
or “PTP2C”) is a member of a small subfamily of cy-
tosolic protein tyrosine phosphatases (PTPs) that includes
SHP-1 (encoded by PTPN6) and the Drosophila SHP-
2–homolog corkscrew (csw). These proteins exhibit a
high degree of homology in amino acid sequence; share
a common structure composed of two tandemly arranged
amino-terminal src-homology 2 (SH2) domains (N-SH2
and C-SH2), a PTP, and a carboxy-terminal tail (Stein-
Gerlach et al. 1998; Feng 1999); and are essential during
development (Kozlowski et al. 1993; Tsui et al. 1993;
Tang et al. 1995; Arrandale et al. 1996; Perkins et al.
1996; Saxton et al. 1997). In contrast to SHP-1, which
is expressed primarily in the hematopoietic cell lineage,
SHP-2 is ubiquitously expressed and is involved in me-
sodermal patterning (Tang et al. 1995), limbdevelopment
(Saxton et al. 2000), hematopoietic cell differentiation
(Qu and Feng 1998; Qu et al. 1998), and semilunar val-
vulogenesis (Chen et al. 2000). SHP-2 is a key molecule
in the cellular response to growth factors, hormones, cy-
tokines, and cell adhesion molecules. It is required for
activation of the Ras/mitogen-activated protein (MAP)
kinase cascade induced by epidermal, fibroblast, and he-
patocyte growth factors (Maroun et al. 2000; Shi et al.
2000; Cunnick et al. 2002). Depending on its subcellular
localization and binding partners, SHP-2 can also neg-
atively modulate signaling (Milarski and Saltiel 1994;
Stofega et al. 2000; Maile and Clemmons 2002).
Activation of SHP-2 results from binding of the SH2
domains to short amino acid motifs containing a phos-
photyrosyl residue. Although both SH2 domains posi-
tively modulate the level of phosphatase activity of SHP-
2 (Pluskey et al. 1995), theN-SH2 domain has themajor
role in the control of its activation. Crystallographic
data on SHP-2 indicate that theN-SH2 domain interacts
with the PTP domain in the inactive conformation,
blocking the catalytic site (Hof et al. 1998). After the
N-SH2 domain binds a phosphotyrosyl residue, a con-
formational change that reduces the intermolecular in-
teraction between the N-SH2 and PTP domains makes
the catalytic site available to substrate. Thus, the N-
SH2 domain acts as a molecular switch, activating and
inactivating SHP-2. The PTPN11 mutations that cause
NS clustered in the interacting portions of the N-SH2
and PTP domains, and energetics-based structural anal-
ysis suggested that these mutations would stabilize SHP-
2 in the active conformation (Tartaglia et al. 2001).
Thus, it was proposed that the PTPN11 mutations in
NS induce a gain of function.
For the present study, we screened for PTPN11 cod-
ing-region defects in a large, well-characterized cohort
of individuals with sporadic or familial NS. Our results
define more accurately the range of molecular defects
causing NS and establish a correlation between geno-
type and the cardiac phenotypes, pulmonic stenosis, and
hypertrophic cardiomyopathy. In addition, we show
that a family with a NS-related disorder, Noonan-like/
multiple giant-cell lesion syndrome (MIM 163955), in-
herited a PTPN11 mutation that segregated with the
phenotype.
Material and Methods
Clinical Evaluation
Subjects were examined by clinicians (M.A.P. and
I.vdB.) experienced with NS. Electrocardiograms, ech-
ocardiograms, and clinical photographs were obtained
routinely for the probands, as well as for most of other
affected family members in the kindreds segregating the
disorder. NS was diagnosed on the basis of the pres-
ence of the following major characteristics: typical facial
dysmorphia, pulmonic stenosis or HCM plus abnormal
electrocardiogram pattern, pectus carinatum/excava-
tum, height 12 SD below the mean, and cryptorchidism
in male subjects. To have a diagnosis of NS, individuals
with typical facial dysmorphia had to have at least one
additional major feature, whereas individuals with sug-
gestive facial findings had to have at least two other
major characteristics (van der Burgt et al. 1994). HCM
was diagnosed when the left-ventricular maximal end
diastolic wall thickness was 11.5 cm in adults (Shapiro
and McKenna 1983) or 12 SD above the mean for a
given age in children (Burch et al. 1993). The clinical
description of a kindred with Noonan-like/multiple gi-
ant-cell lesion syndrome was reported elsewhere (Bertola
et al. 2001). Informed consent was obtained from all
subjects included in the study.
Mutational Analysis
Genomic DNAs were isolated from peripheral blood
lymphocytes (Gentra). The entirePTPN11 coding region
(exons 1–15) was screened for mutations. For exons
2–15, PCRs were performed in a 25-ml reaction volume
containing 20–80 ng genomic DNA, 1 U AmpliTaqGold
(Roche), 20 pmol each primer, 1.5 mM MgCl2, 75 mM
each dNTP, and 1# PCR Buffer II (Roche), through use
of a GeneAmp PCR System 9700 (Applied Biosystems).
Exon 1 amplifications were performed using the GC-
rich PCR System (Roche), according to the manufac-
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Table 1
Primer Pairs and Annealing Temperatures Used to Amplify the PTPN11 Coding Sequence and Sizes of PCR Products
EXON
PRIMER SEQUENCE
(5′r3′)
ANNEALING
TEMPERATURE
(C)
PRODUCT
LENGTH
(bp)Forward Reverse
1 GCTGACGGGAAGCAGGAAGTGG CTGGCACCCGTGGTTCCCTC 60 589
2 ACTGAATCCCAGGTCTCTACCAAG CAGCAAGCTATCCAAGCATGGT 60 405
3 CGACGTGGAAGATGAGATCTGA CAGTCACAAGCCTTTGGAGTCAG 60 384
4 AGGAGAGCTGACTGTATACAGTAG CATCTGTAGGTGATAGAGCAAGA 58 447
5 CTGCAGTGAACATGAGAGTGCTTG GTTGAAGCTGCAATGGGTACATG 60 329
6 TGCATTAACACCGTTTTCTGT GTCAGTTTCAAGTCTCTCAGGTC 54 282
7 GAACATTTCCTAGGATGAATTCC GGTACAGAGGTGCTAGGAATCA 56 271
8 GACATCAGGCAGTGTTCACGTTAC CCTTAAAGTTACTTTCAGGACATG 57 350
9 GTAAGCTTTGCTTTTCACAGTG CTAAACATGGCCAATCTGACATGTC 56 357
10 GCAAGACTTGAACATTTGTTTGTTGC GACCCTGAATTCCTACACACCATC 60 284
11 CAAAAGGAGACGAGTTCTGGGAAC GCAGTTGCTCTATGCCTCAAACAG 60 453
12 GCTCCAAAGAGTAGACATTGTTTC GACTGTTTTCGTGAGCACTTTC 56 250
13 CAACACTGTAGCCATTGCAACA CGTATCCAAGAGGCCTAGCAAG 60 356
14a ACCATTGTCCCTCACATGTGC CAGTGAAAGGCATGTGCTACAAAC 60 259
15 CAGGTCCTAGGCACAGGAACTG ACATTCCCAAATTGCTTGCCT 60 321
a GC clamps were added at the 5′ end for DHPLC analysis: forward primer, 5′-CCCGCCGCCCCCGCCG-3′; reverse primer,
5′-CCGCGCCCCCGCCCG-3′ (product length p 290 bp).
Table 2
Percent Buffer B and Temperatures Used in DHPLC
Analysis for PTPN11 Mutation Detection
EXON
% BUFFER Ba
TEMPERATURE(S)
(C)Loading Initial Final
1 56 61 67 67
2 55 60 66 56, 57
3 54 59 65 57, 58
4 53 58 64 56, 57
5 51 56 62 56, 58
6 50 55 61 56, 57
7 50 55 61 56, 57
8 51 56 62 57, 58
9 52 57 63 56, 57
10 50 55 61 57, 58
11 54 59 65 59
49 54 60 64
12 48 53 59 58, 59
13 51 56 62 59
50 55 61 60
14 52 57 63 57
49 54 60 60
15 51 56 62 56, 57
a % buffer B.buffer Ap 100%
turer’s specifications. Cycling parameters were as fol-
lows: 94C for 8 min (first denaturing step); 33 cycles
of 94C for 45 s, 54–60C (see table 1) for 30 s, and
72C for 45 s; and 72C for 10 min (last extension step).
Primer pairs were designed to amplify exons, exon/in-
tron boundaries, and short intron flanking stretches.
Primer sequences, annealing temperatures, and sizes of
PCR products are listed in table 1.
Mutational analysis of the amplimers was performed
by means of denaturing high-performance liquid chro-
matography (DHPLC), through use of the Wave DNA
Fragment Analysis System (Transgenomics) at column
temperatures recommended by the WaveMaker version
4.1.31 software (Transgenomics). DHPLC buffers and
run conditions were as follows: buffer A (0.1M trieth-
ylammonium acetate [TEAA], 0.025% acetonitrile
[ACN]), buffer B (0.1M TEAA, 25% ACN); a flow rate
of 0.9 ml/min; and a gradient duration of 3 min, with
active clean (75% ACN). Buffer B gradients and tem-
peratures are reported in table 2. Positive controls—that
is, PCR products expected to result in variant elution
profiles—were used in all DHPLC runs. Heterozygous
templates with previously identified mutations or single-
nucleotide polymorphisms (SNPs) were used as positive
controls for exons 3, 4, 7, 8, and 13. For each of the
remaining exons, a synthetic template containing a single
nucleotide change was constructed using the overlap ex-
tension method in a two-step PCR procedure. Wild-type
and mutated PCR products were denatured together at
94C for 5 min and were slowly cooled at room tem-
perature, to allow heteroduplex formation. Bidirectional
direct sequencing of purified PCR products (Qiagen)was
performed using the ABI BigDye Terminator Sequenc-
ing Kit (Perkin Elmer) and an ABI 3700 Capillary Ar-
ray Sequencer (Perkin Elmer). Sequences were analyzed
by the Sequencing Analysis v.3.6.1 and AutoAssem-
bler v.1.4.0 software packages (Perkin Elmer). Cosegre-
gation analysis and exclusion of the mutations in control
samples ( ) were performed by means of RFLP,np 100
DHPLC, or direct sequencing.
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Table 3
PTPN11 Mutations in NS
Nucleotide
Substitution
No. of
Cases
Amino Acid
Substitution Domain
Exon 2:
124ArG 2 Thr42Ala N-SH2
Exon 3:
179GrC 2 Gly60Ala N-SH2
181GrA 1 Asp61Asn N-SH2
182ArG 2 Asp61Gly N-SH2
184TrG 2 Tyr62Asp N-SH2
188ArG 4 Tyr63Cys N-SH2
215CrG 1 Ala72Gly N-SH2
218CrT 1 Thr73Ile N-SH2
228GrC 1 Glu76Asp N-SH2
236ArG 5 Gln79Arg N-SH2
317ArC 3 Asp106Ala N-SH2/C-SH2 linker
Exon 4:
417GrC 1 Glu139Asp C-SH2
417GrT 1 Glu139Asp C-SH2
Exon 7:
836ArG 1 Tyr279Cys PTP
844ArG 1 Ile282Val PTP
853TrC 1 Phe285Leu PTP
Exon 8:
854TrC 1 Phe285Ser PTP
922ArG 17 Asn308Asp PTP
923ArGa 2 Asn308Ser PTP
925ArG 1 Ile309Val PTP
Exon 13:
1502GrA 1 Arg501Lys PTP
1510ArG 3 Met504Val PTP
a Affected members of one family segregating the 923ArG change
(Asn308Ser) exhibited the Noonan-like/multiple giant-cell lesion
condition.
Figure 1 Cosegregation of PTPN11mutations andNoonanphe-
notype. A, Restriction analysis of PTPN11 PCR product containing
exon 8, showing segregation of the 922ArG mutation in the original
large family with NS that shows linkage to 12q24 (Jamieson et al.
1994). The family tree is shown above. The mutation introduces an
EcoRV restriction site, resulting in 246- and 366-bp products, whereas
the wild-type allele remains undigested (612 bp). B, DHPLC elution
profiles of PTPN11 exon 8 PCR products, showing segregation of the
923ArG change in a family inheriting Noonan-like/multiple giant-cell
lesion syndrome (Bertola et al. 2001). A single peak characterizes the
wild-type profile, and a variant profile, characterized by two peaks, is
observed in all affected family members. The family tree is shown on
the left. The gray-shaded symbol indicates an indeterminatephenotype.
Genotype-phenotype correlations were performed us-
ing 2#2 contingency-table analysis. The significance
threshold was set at .P ! .05
Results
Spectrum of PTPN11 Mutations
The study population comprised 119 propositi with
NS, including 70 with sporadic NS and 49 apparently
unrelated families. Of the familial cases, the phenotype
was linked to the NS1 locus in 11. Linkage exclusion
for the NS1 locus was documented in four families. The
small size of the remaining 34 families (typically, an af-
fected parent and child) did not allow for linkage anal-
ysis. All subjects were of northern-European descent,
except for two, one of Afro-Caribbean and one of Indian
origin.
DNAs from the 119 propositi with NS were screened
for PTPN11 coding-region mutations. Exons 1–15 and
flanking intron sequences were PCR amplified and were
analyzed by means of DHPLC, and products with variant
elution profiles were sequenced bidirectionally. PTPN11
mutations were identified in 54 subjects, comprising 22
different nucleotide changes (table 3). All mutations were
missense exonic changes, with the majority clustering in
exons 3 and 8. The mutations cosegregated completely
with the disease in all familial cases. None of the 22 dif-
ferent mutations was observed in at least 100 control
Europeans or Americans of European descent. Parental
DNAs were available for 43 of 52 (83%) individuals with
sporadic NS who had PTPN11 mutations. Only one par-
ent was identified as carrying a mutation—the 925ArG
transition, predicting an Ile309Val substitution. The var-
iant profile for this mutation was not observed in 1400
control chromosomes.
The ArG transition at position 922 in exon 8, pre-
dicting the Asn308Asp substitution within the PTP do-
main, was the most common mutation, accounting for
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Figure 2 Location of mutated residues in SHP-2 in the inactive
conformation: Ca trace of the N-SH2 (thin blue line), C-SH2 (thin
magenta line), and PTP (thin orange line) domains; and N-SH2/C-SH2
and C-SH2/PTP linkers (thin gray lines), according toHof et al. (1998).
The views represented in panels A and B are orthogonal to each other.
Mutated residues are indicated with their side chains as thick lines (N-
SH2 residues located in or close to the N-SH2/PTP interaction surface
are shown in white; linker, C-SH2, and N-SH2-phosphopeptide bind-
ing residues are shown in green; and PTP residues located in or close
to the N-SH2/PTP interaction surface are shown in red).
Table 4
Polymorphisms in the PTPN11 Gene
Location Nucleotide Change
Exon 1 (5′ UTR) 140delGa
Intron 1 25GrC
Intron 1 54CrA
Exon 3 255CrT (His85)
Intron 4 12GrC
Intron 4 78ArG
Intron 7 21CrT
Intron 7 30TrC
Intron 7 32ArC
Intron 7 35ArC
Intron 7 132TrC
Intron 9 9CrA
Intron 10 63GrA
Intron 13 26GrA
Intron 15 40TrC
a Position refers to the A of the ATG
initiator codon.
one-third of the total. Of note, the Asn308Asp mutation
was identified in the large three-generation family that
was used to originally establish linkage to theNS1 locus
(Jamieson et al. 1994; van der Burgt et al. 1994) (fig.
1A). The two occurrences of the adjacent 923ArG mu-
tation, predicting an Asn308Ser change, indicate that
codon 308 represents a hotspot for NS.
Eight additional mutations were found recurrent-
ly. Among them, the 182ArG (Asp61Gly), 188ArG
(Tyr63Cys), and 236ArG (Gln79Arg) substitutions in
exon 3, as well as the 1510ArG (Met504Val) change
in exon 13, have previously been reported as disease-
causing mutations (Tartaglia et al. 2001). Interestingly,
90% of mutational events involved amino acid residues
located in the N-SH2 and PTP functional domains (fig.
2). The exceptions were the 317ArC transversion, ob-
served in two individuals with sporadic NS and in one
family, predicting an Asp106Ala substitution in the
peptide linking the N-SH2 and C-SH2 domains, and
the 417GrC and 417GrT changes, both predicting a
Glu139Asp substitution within the C-SH2 domain.
On the basis of the secondary structure of SHP-2 in
the inactive conformation determined by Hof et al.
(1998), the N-SH2 and PTP mutations were noted to
cluster dramatically in specific regions of those domains.
Of the 10 N-SH2 substitutions, 5 were positioned in the
D′E loop and flanking bD′ and bE strands (residues
57–65), and 4were in the bF strand andaB helix (residues
69–84). The nine PTP mutations were restricted to the
DB loop (residues 277–288; ), bC strand (residuesnp 4
303–311; ), and HI loop (residues 499–507,np 3 np
). Most strikingly, all N-SH2 and PTP mutations except2
the Thr42Ala substitution involved residues located in or
close to the N-SH2/PTP interacting surface (fig. 2).
Fifteen sequence variants that are likely to represent
neutral polymorphisms were observed in subjects with
NS, unaffected family members, and control individuals
(table 4). These changes included 13 intronic SNPs, a
single-base deletion within the 5′ UTR, and a synony-
mous change in exon 3.
Genetic Heterogeneity in NS
PTPN11 mutations were detected in the 11 families
for which the disorder appeared to be linked to theNS1
locus, including the original large family described by
Jamieson et al. (1994). As anticipated, no PTPN11 se-
quence change was observed in the four families for
which linkage to NS1 had been excluded. For the entire
study group of 119, PTPN11 mutations were observed
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Table 5
Clinical Features in Subjects with NS with and without PTPN11
Mutations
CLINICAL FEATURE
NO./TOTAL (%) OF SUBJECTS
Pa
With PTPN11
Mutation
Without PTPN11
Mutation
Cardiac defects:
HCM 3/51 (5.9) 17/65 (26.1) .004
Pulmonic stenosis 36/51 (70.6) 30/65 (46.2) .008
Septal defects 6/50 (12.0) 11/63 (17.5) NS
Short stature 39/51 (76.5) 45/64 (70.3) NS
Special education 11/46 (23.9) 21/59 (35.6) NS
Pectus deformities 39/50 (78.0) 46/61 (75.4) NS
Cryptorchidism 26/31 (83.9) 25/35 (71.4) NS
a “NS” indicates a difference that is not statistically significant.
in 45%, a slightly lower incidence than had been seen
in a small cohort (Tartaglia et al. 2001). PTPN11 mu-
tations were detected in 59% of individuals with familial
NS, whereas such defects were observed in only 37% of
individuals with sporadic NS. This statistically signifi-
cant ( ) difference in PTPN11 mutation preva-P ! .02
lence suggests that the additional gene or genes respon-
sible for NS engender incomplete penetrance or have
greater adverse affects on fertility than does PTPN11.
Genotype-Phenotype Correlation
Because of the clinical heterogeneity observed in NS,
we investigated possible associations between genotype
and phenotype. The distribution of several major clinical
features of NS, in subjects with and without mutations
in PTPN11, is shown in table 5. A statistically significant
associationwith pulmonic stenosiswas found in the group
with PTPN11 mutations (70.6% vs. 46.2%; ).Pp .008
In contrast, a statistically significantly lower incidence of
HCM was observed in this group (5.9% vs. 26.2%;
). Therewas no significant difference in theprev-Pp .004
alence of atrial and/or ventricular septal defects or other
congenital heart malformations between the groups with
and without PTPN11 mutations. Similarly, there was no
difference in the rates of short stature, pectus deformities,
cryptorchidism, or enrollment in special education (as a
marker of developmental delay).
The clinical manifestations of NS were compared be-
tween the cohort with N-SH2 mutations and the cohort
with PTP mutations. Although this analysis had less sta-
tistical power, owing to sample size, no significant dif-
ferences were identified. The phenotype observed in sub-
jects with the common Asn308Asp substitution (np
) was not qualitatively different from the phenotype17
in subjects with other mutations, except for the fact that
no subject carrying the Asn308Asp change was enrolled
in special education.
We identified an ArG transition at position 923
(Asn308Ser) in a family with typical features of NS as-
sociated with multiple giant-cell lesions in bone (Bertola
et al. 2001). This mutation cosegregated perfectly with
this phenotype (fig. 1B). One family member (III-3) had
a typical NS phenotype (i.e., pulmonic stenosis, crypt-
orchidism, short stature, and distinctive face and chest
deformity) and exhibited asymptomatic lesions in the
right ramus of the mandible and in the maxilla, as well
as osteolytic lesions in both humeri and in the left fe-
mur. Similarly, his affected sister (III-2) had multiple le-
sions in the mandible. Serum calcium, phosphate, and
PTH levels were normal in both subjects. Their moth-
er (II-2) had typical NS features but did not have any
bone lesions. The same Asn308Ser mutation was ob-
served in another family with NS that had no known
bony involvement.
Discussion
Recently, we established that missense mutations in
PTPN11 cause NS and implicated a gain-of-function
mechanism. In the present study, we extend those ini-
tial observations in several important respects. These
include a more complete assessment of the range of
PTPN11 lesions causing NS, evaluation of disease pen-
etrance, establishment of genotype-phenotype corre-
lation, and broadening of the phenotype associated
with PTPN11 mutations to include NS with multiple
giant-cell lesions.
In our present analysis of a large cohort with sporadic
and familial cases of NS, we estimated the PTPN11
mutation prevalence to be 45%. Although it is quite
similar to the rate of 50% observed in a small cohort
with NS, there are some limitations to the accuracy of
this estimate. In the present study, DHPLC was used to
screen the PTPN11 coding exons. Since this method is
purported to have a sensitivity of 96%–100% under
ideal conditions (Xiao and Oefner 2001), the true prev-
alence of point mutations in this cohort could be slightly
higher. Second, no attempt was made to look for other
types of molecular lesions that might also cause NS,
such as large intragenic deletions, changes in the 3′UTR,
or promoter defects. Lastly, our current results revealed
that the prevalence detected in any NS cohort would be
sensitive to the composition of sporadic and familial
cases. Since the subjects in our cohort were not ascer-
tained in a cross-sectional manner (i.e., there was prob-
ably a systematic bias toward familial cases), our prev-
alence figure could be an overestimate.With those issues
stipulated, the contribution of PTPN11 mutations to
the etiology of NS appears to be ∼50%.
When these results are combined with our previous
work, we have now identified 78 unrelated individuals
with NS who have mutations in PTPN11. All mutations
are missense changes that affect amino acid residues that
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are conserved among the vertebrate SHP-2 orthologs.
Most altered residues are also conserved among the ver-
tebrate SHP-1 proteins. Previously, we had argued that
the NS-causing PTPN11 defects result in gain-of-func-
tion effects on SHP-2. This was supported by energetics-
based structural analysis of two mutants (Tartaglia et al.
2001) and by the observation that two NS mutant alleles
closely resembled two engineered SHP-2 mutants with
increased phosphatase activity in vitro and inductive ef-
fects inXenopus animal caps (O’Reilly et al. 2000). Since
we have failed to identify any nonsense, frameshift, or
splicing defect among 78 PTPN11 mutations, it seems
highly unlikely that SHP-2 haploinsufficiency results in
the NS phenotype.
The distribution of the altered amino acid residues in
SHP-2 has a nonrandom pattern (table 3 and fig. 2).
The vast majority of the NS mutations clustered in the
N-SH2 and PTP functional domains but were not re-
stricted to those domains, as was seen previously. The
N-SH2 domain interacts with the PTP domain and
binds to phosphotyrosyl-containing targets on activated
receptors or docking proteins, using two separate sites.
These sites show negative cooperativity, so that N-SH2
can work as intramolecular switch to control SHP-2
catalytic activity. In the inactive state, the N-SH2 and
PTP domains share a broad interaction surface. More
precisely, the N-SH2 D′E loop and flanking bD′ and bE
strands closely interact with the catalytic cleft, blocking
the PTP active site. Crystallographic data on SHP-2 in
the inactive conformation revealed a complex interdo-
main hydrogen-bonding network—involving Asn58,
Gly60, Asp61, Cys459, and Gln506—that stabilizes the
protein (Hof et al. 1998). Numerous polar interactions
between N-SH2 residues located in strands bF and bA,
helix aB, and residues of the PTP domain further sta-
bilize the inactive conformation. Significantly, most of
the residues mutated in NS are either directly involved
in these interdomain interactions (i.e., Gly60, Asp61,
Ala72, Glu76, and Gln79) or in close spatial proximity
to them (i.e., Tyr62, Tyr63, Thr73, Tyr279, Ile282,
Phe285, Asn308, Ile309, Arg501, and Met504). This
distribution of molecular lesions suggests that the path-
ogenetic mechanism in NS involves altered N-SH2/PTP
interactions that destabilize the inactive conformation
without altering SHP-2’s catalytic capability. Consistent
with this view, no mutation altered Cys459 (the residue
essential for nucleophilic attack), the PTP signature mo-
tif (positions 457–467), or the TrpProAsp loop (posi-
tions 423–425), which are all essential for phosphatase
activity.
Three of the NS mutations affected residues outside of
the interacting regions of the N-SH2 and PTP domains.
One recurrent mutation affected Asp106, which is lo-
cated in the linker stretch connecting the N-SH2 and C-
SH2 domains. Although functional studies are required
to understand the functional significance of the AsprAla
substitution, we hypothesize that this mutation might
alter the flexibility of the N-SH2 domain, thus inhibit-
ing the N-SH2/PTP interaction. Two mutated residues,
Thr42 (N-SH2 domain) and Glu139 (C-SH2 domain),
are spatially far from the N-SH2/PTP interaction sur-
faces. In contrast to the other mutated residues, Thr42
and Glu139 are implicated in the intermolecular inter-
actions of the SH2 domains with phosphotyrosyl-con-
taining peptides (Lee et al. 1994; Huyer and Ramachan-
dran 1998). Specifically, Thr42 directly interacts with the
tyrosine phosphate, and Glu139 is adjacent to Arg138
and Ser140, which form hydrogen bonds to that phos-
phate. Since the phenotype of the subjects bearing these
mutations was typical for NS, molecular characterization
is needed in order to understand how defects in phos-
photyrosine binding result in developmental perturba-
tions similar to those affecting SHP-2 inactivation.
Previously, the penetrance of NS had not been ad-
dressed in a systematic fashion. Two lines of evidence
now suggest that NS caused by PTPN11 mutations is
almost completely penetrant. First, we analyzed 11 fam-
ilies, including the large kindred first described by van
der Burgt et al. (1994), for which significant or sug-
gestive linkage to the NS1 locus had been established
(Jamieson et al. 1994). In each instance, a PTPN11
mutation was identified that was inherited by all of the
affected individuals in the family but by none of the
unaffected ones. Analysis of small kindreds harboring
PTPN11 mutations revealed the same consistent pat-
tern. Second, we genotyped a high percentage (83%) of
the unaffected parents for defects discovered in their
offspring with apparently sporadic NS. In only one in-
stance was a mutation identified. Although it is possible
that inclusion of “milder” cases of NS might have un-
covered some instances of incomplete penetrance, the
strict criteria for NS employed in the present study iden-
tified a cohort with almost 100% penetrance.
We observed a statistically significantly higher inci-
dence of pulmonic stenosis among subjects with NS in-
heriting PTPN11mutations. Experimental evidencewith
mice indicates that epidermal growth factor (EGF) sig-
naling is important for semilunar valve development and
that SHP-2 is a component of the EGF-mediated signal
transduction pathway (Qu et al. 1999; Chen et al. 2000).
A proportion of mice that are homozygous for a hypo-
morphic Egfr allele exhibit thickened aortic and pul-
monary valve leaflets because of an increased number of
mesenchymal cells. Coinheritance of a Ptpn11 knock-
out allele in heterozygosity results in a higher prevalence
and increased severity of those valve abnormalities. These
findings implicate SHP-2 in aspects of EGF-mediated
semilunar valvulogenesis, such as mesenchymal trans-
formation and proliferation, as well as leaflet remodel-
ing. The specific manner in which the gain-of-function
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PTPN11 changes observed in NS result in pulmonic ste-
nosis (but not aortic stenosis) remains to be determined.
An understanding of the relatively reduced prevalence of
pulmonic stenosis in other genetic forms of NS must
await an elucidation of those disease genes. Similarly, the
reduced prevalence of HCM in the cohort with PTPN11
mutations suggests that SHP-2 plays less of a role in
cardiomyocyte proliferation than do other NS disease
genes.
Finally, we demonstrated the cosegregation of a
923ArG PTPN11 mutation in a family inheriting the
Noonan-like/multiple giant-cell lesion syndrome. Since
a 923ArG mutation was also identified in an unrelated
kindred with classic NS, additional genetic factors or
events may be necessary to result in the proliferation of
these giant cells. Only a single family with this rare
phenotype was available for genotyping, so the per-
centage of cases attributable to PTPN11 defects remains
to be determined. Although the Noonan-like/multiple
giant-cell lesion syndrome was introduced as a distinct
entity characterized by the association of some cardinal
features of NS with giant-cell lesions of bone and soft
tissues (Cohen et al. 1974; Cohen and Gorlin 1991), it
can now be viewed as part of the NS spectrum. This
result implies that mutation screening of PTPN11 for
other NS-like conditions, such as the cardio-facio-cu-
taneous, Leopard, and Noonan/NF1 syndromes, is nec-
essary to elucidate whether those entities are distinct
nosologic conditions, allelic disorders, or extreme phe-
notypes of a single disorder with markedly variable
expressivity.
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